Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Germany's military, the Bundeswehr (Federal Defence), is organised into the Heer (Army and special forces KSK), Marine (Navy), Luftwaffe (Air Force) and Cyber- und Informationsraum (Cyber and Information Domain Service) branches. In absolute terms, German military spending in 2025 was the fourth-highest in the world. In response to the 2022 Russian invasion of Ukraine, Chancellor Olaf Scholz announced that German military expenditure would be increased past the NATO target of 2%, along with a one-time 2022 infusion of 100 billion euros, representing almost double the 53 billion euro military budget for 2021. In 2023, military spending according to NATO criteria amounted to $73.1 billion, or 1.64% of the country's GDP, well below the NATO target of 2%. In 2026, Germany reported an estimated spending of $147.002 billion to NATO, exceeding said target at 2.69% of GDP. As of May 2024, the Bundeswehr has a strength of 180,215 active soldiers and 80,761 civilians. Reservists are available to the armed forces and participate in defence exercises and deployments abroad. Until 2011, military service was compulsory for men at age 18, but this has been officially suspended and replaced with a voluntary service. Since 2001 women may serve in all functions of service without restriction. According to the Stockholm International Peace Research Institute, Germany was the fourth-largest exporter of major arms in the world between 2021 and 2025. In peacetime, the Bundeswehr is commanded by the Minister of Defence.
== ICH GCP overview == Glossary Principles of ICH GCP Guidelines for: institutional review board (IRB) / independent ethics committee (IEC) investigator trial sponsor (industrial, academic) clinical trial protocol and protocol amendments investigator's brochure essential documents
== Notable achievements and awards == In 1996, Kessler became a member of the Bavarian Academy of Sciences and Humanities, one of the eight state academies in Germany. In 2002, he was elected to membership of the Academy of Sciences Leopoldina, the national academy of Germany.
Sources: en.wikipedia.org
The wide occurrence of glycolysis in other species indicates that it is an ancient metabolic pathway. Indeed, the reactions that make up glycolysis and its parallel pathway, the pentose phosphate pathway, can occur in the oxygen-free conditions of the Archean oceans, also in the absence of enzymes, catalyzed by metal ions, meaning this is a plausible prebiotic pathway for abiogenesis. The most common type of glycolysis is the Embden–Meyerhof–Parnas (EMP) pathway, which was discovered by Gustav Embden, Otto Meyerhof, and Jakub Karol Parnas. Glycolysis also refers to other pathways, such as the Entner–Doudoroff pathway and various heterofermentative and homofermentative pathways. However, the discussion here will be limited to the Embden–Meyerhof–Parnas pathway. The glycolysis pathway can be separated into two phases:
Polonium is "distinctly metallic" in some ways. Both of its allotropic forms are metallic conductors. It is soluble in acids, forming the rose-coloured Po2+ cation and displacing hydrogen: Po + 2 H+ → Po2+ + H2. Many polonium salts are known. The oxide PoO2 is predominantly basic in nature. Polonium is a reluctant oxidizing agent, unlike its lightest congener oxygen: highly reducing conditions are required for the formation of the Po2− anion in aqueous solution. Whether polonium is ductile or brittle is unclear. It is predicted to be ductile based on its calculated elastic constants. It has a simple cubic crystalline structure. Such a structure has few slip systems and "leads to very low ductility and hence low fracture resistance". Polonium shows nonmetallic character in its halides, and by the existence of polonides. The halides have properties generally characteristic of nonmetal halides (being volatile, easily hydrolyzed, and soluble in organic solvents). Many metal polonides, obtained by heating the elements together at 500–1,000 °C, and containing the Po2− anion, are also known.
Osteopromotive describes a material that promotes the de novo formation of bone. Osteoconductivity describes the property of graft material in which it serves as a scaffold for new bone growth but does not induce bone growth de novo. This means that osteoconductive materials will only contribute to new bone growth in an area where there is already vital bone. Osteoinductivity describes the property of graft material in which it induces de novo bone growth with biomimetic substances, such as bone morphogenetic proteins. Such materials will contribute to new bone growth in an area where there is no vital bone, such as when implanted into muscle tissue. In contrast, osteopromotive substances will not contribute to de novo bone growth but serve to enhance the osteoinductivity of osteoinductive materials. An example of this is enamel matrix derivative, which serves to enhance the osteoinductive nature of demineralized freeze dried bone allograft (DFDBA).
Formaldehyde is banned from use in certain applications (preservatives for liquid-cooling and processing systems, slimicides, metalworking-fluid preservatives, and antifouling products) under the Biocidal Products Directive. In the EU, the maximum allowed concentration of formaldehyde in finished products is 0.2%, and any product that exceeds 0.05% has to include a warning that the product contains formaldehyde. In the United States, Congress passed a bill July 7, 2010, regarding the use of formaldehyde in hardwood plywood, particle board, and medium-density fiberboard. The bill limited the allowable amount of formaldehyde emissions from these wood products to 0.09 ppm, and required companies to meet this standard by January 2013. The final US EPA rule specified maximum emissions of "0.05 ppm formaldehyde for hardwood plywood, 0.09 ppm formaldehyde for particleboard, 0.11 ppm formaldehyde for medium-density fiberboard, and 0.13 ppm formaldehyde for thin medium-density fiberboard." Formaldehyde was declared a toxic substance by the 1999 Canadian Environmental Protection Act. The FDA is proposing a ban on hair relaxers with formaldehyde due to cancer concerns.
Sources: en.wikipedia.org
colligative property Any property of a solution that depends upon the ratio of the number of solute particles to the number of solvent particles in the solution, and not on the nature of the chemical species present. Examples include osmotic pressure, freezing-point depression, and boiling-point elevation.
1 April – Artemis program: NASA launches the Artemis II lunar flyby mission from Launch Complex 39B at the Kennedy Space Center in Florida, the first crewed flight beyond low Earth orbit since Apollo 17 in 1972. With a crew of four astronauts – Reid Wiseman (Commander) Victor Glover (Pilot), Christina Koch (Mission specialist), and Canadian astronaut Jeremy Hansen (Mission specialist) – it also becomes the first time a person of color, a woman, and a non-United States citizen have left low Earth orbit. It passed around the Moon's far side on April 6. 2 April Scientists describe a transitional fauna of the late Ediacaran from Yunnan in China, which fills a gap between ancestors of modern phyla and larger multicellular life. Astronomers using preliminary data from the Vera C. Rubin Observatory announce the discovery of over 11,000 new asteroids, including hundreds of trans-Neptunian objects and 33 previously unknown near-Earth objects. The detections are confirmed by the Minor Planet Center. 6 April – In a landmark achievement for India's nuclear energy programme, the 500 MWe Prototype Fast Breeder Reactor successfully attains first criticality (start of controlled fission chain reaction). 6 April – The crew of Artemis II breaks the record for the furthest humans have ever been from Earth, reaching a maximum distance of 252,757 miles (406,773 km) as they travel around the far side of the Moon.
The concept of health technology assessment (HTA) was first coined in 1967 by the U.S. Congress in response to the increasing need to address the unintended and potential consequences of health technology, along with its prominent role in society. It was further institutionalized with the establishment of the congressional Office of Technology Assessment (OTA) in 1972–1973. HTA is defined as a comprehensive form of policy research that examines short- and long-term consequences of the application of technology, including benefits, costs, and risks. Due to the broad scope of technology assessment, it requires the participation of individuals besides scientists and health care practitioners such as managers and even the consumers. Several American organizations provide health technology assessments and these include the Centers for Medicare and Medicaid Services (CMS) and the Veterans Administration through its VA Technology Assessment Program (VATAP). The models adopted by these institutions vary, although they focus on whether a medical technology being offered is therapeutically relevant. A study conducted in 2007 noted that the assessments still did not use formal economic analyses. Aside from its development, however, assessment in the health technology industry has been viewed as sporadic and fragmented Issues such as the determination of products that needed to be developed, cost, and access, among others, also emerged.
Medical withdrawal management ensures safety and comfort by providing long-term monitoring until the symptoms of withdrawals are over. An important part of treatment for addiction is counseling. Methadone clinics are only for recovering addicts from opioids. Clinics require attendance at counseling groups as well as individual counseling contacts. It is generally accepted that the more intensive the counseling contacts the individual is willing to submit to, the higher the success rate of the program. Also, an integral part of counseling is on preventing the exposure and transmission of HIV. Clinics should be able to provide or refer patients to various services: community resources, vocational rehabilitation, education, employment, and prenatal-care. There is no set guideline for duration of methadone treatment, however, longer treatments are associated with better outcomes. Patients receiving methadone treatment in a closed setting should be assisted when transferring to a community-based setting. Patients who voluntarily decide to stop methadone treatment should speak to their provider to discuss why they want to stop and other treatment options. Access to methadone treatment in the United States varies considerably by state, and research suggests that states with policies expanding access have seen meaningfully better outcomes for patients with opioid use disorder. Stigma surrounding opioid addiction may pose additional barriers beyond geography and cost.
The Dirty Drug and the Ice Cream Tub Radiolab episode on the discovery of rapamycin Clinical trial number NCT02494570 for "A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa (AMPECT)" at ClinicalTrials.gov
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.